InMed Pharmaceuticals Inc. (INM) shares slipped in early Nasdaq pre-market trading on Wednesday, retreating from a massive rally sparked by its all-stock merger agreement with privately held Mentari Therapeutics and a planned $290 million private placement.
At 6:07 a.m. EDT, InMed traded at $1.37, down 14.4% from Tuesday's close of $1.60. The stock had surged 135.1% on Tuesday, with volume of 93.1 million shares, after closing at $0.681 the previous day.
Merger Terms and Ownership Structure
The transaction is structured as an all-stock merger, meaning InMed shareholders are not receiving cash. Instead, the combined entity will operate as Mentari Therapeutics and focus on migraine drug development. Pre-merger InMed shareholders are expected to own approximately 1.51% of the combined company, which will trade on the Nasdaq Capital Market under a new ticker.
The deal is expected to close in the second half of 2026, subject to shareholder approvals, effectiveness of an SEC registration statement, Nasdaq listing approval, and other conditions.
Financing and Cash Position
The private placement component is a key driver of the deal. Mentari's sale of securities to selected investors is expected to raise approximately $290 million, funding operations through 2028 and beyond expected clinical data readouts from its lead migraine programs.
The financing comes at a critical time for InMed, which reported a $3.0 million net loss for the quarter ended March 31. Cash, cash equivalents, and short-term investments stood at $5.2 million at quarter-end, down from $10.8 million at June 30, 2025. The company's latest quarterly filing expressed substantial doubt about its ability to continue as a going concern within one year.
Market Context and Competitive Landscape
Mentari's migraine pipeline targets PACAP and CGRP proteins, both central to migraine biology. The field is competitive, with Eli Lilly (LLY) and Teva (TEVA) as major public-market peers. Their competing migraine drugs, Emgality and Ajovy, were recently embroiled in a revived patent dispute, highlighting both the value and pressure in this therapeutic area.
Broader market conditions were not supportive of risk appetite, with the Nasdaq Composite falling 0.8% on Tuesday to 25,870.71. However, InMed's move was clearly company-specific.
Risks and Uncertainties
The deal faces several potential pitfalls. Shareholders could reject the merger, the private placement might not close as expected, Nasdaq or SEC-related conditions could delay the transaction, and Mentari's drug candidates still face clinical and regulatory risk. Existing InMed holders face a small pro forma ownership stake, with any extra value tied partly to a contingent value right that may pay only if legacy InMed assets produce proceeds.
Late Tuesday, law firm Brodsky & Smith announced it was investigating possible claims against InMed's board over the transaction, including whether the process was fair and whether the proposed transaction pays fair value to shareholders. No lawsuit has been filed.
InMed also separately amended preferred investment options held by Armistice Capital Master Fund, cutting the exercise price to $0.80 from $16.60 for up to 278,761 common shares. The company noted there was no assurance the options would be exercised.
Until key procedural milestones—the Form S-4 filing, shareholder meeting dates, and financing updates—are reached, the stock is trading less like a conventional biotech earnings story and more like a merger-spread and dilution story, with a very small float amplifying price movements.
